Iratumumab

{{Short description|Monoclonal antibody}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{refimprove|date=August 2012}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458270691

| image =

| type = mab

| mab_type = mab

| source = u

| target = CD30

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 640735-09-7

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = AYH22O1B1U

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D04612

| C=6358 | H=9830 | N=1682 | O=1992 | S=38

}}

Iratumumab is a human monoclonal antibody that was investigated for treating oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.{{cite web | title = Statement On A Nonproprietary Name Adopted By The USAN Council – Iratumumab | url = http://www.ama-assn.org/ama1/pub/upload/mm/365/iratumumab.doc | archive-url = https://web.archive.org/web/20110604015047/http://www.ama-assn.org/ama1/pub/upload/mm/365/iratumumab.doc | archive-date = 4 June 2011| publisher = American Medical Association }}{{cite journal | vauthors = Fanale MA, Younes A | title = Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma | journal = Drugs | volume = 67 | issue = 3 | pages = 333–350 | date = 2007 | pmid = 17335294 | doi = 10.2165/00003495-200767030-00002 }}

This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb.

The FDA granted orphan drug designation for Hodgkin's lymphoma in 2004. In 2009, development was suspended with no explanation given.{{cite web | title = Iratumumab | url = http://adisinsight.springer.com/drugs/800017758 | website = AdisInsight | access-date = 30 January 2017 }}